{
    "organizations": [],
    "uuid": "da2d9bd9feca6ac38e64eb7c6a65a5375d630c5e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-generon-corp-says-successfully-con/brief-generon-corp-says-successfully-concluded-first-phase-iii-clinical-trial-of-f-627-idUSASB0C29D",
    "ord_in_thread": 0,
    "title": "BRIEF-Generon Corp Says Successfully Concluded First Phase III Clinical Trial Of F-627",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) -\n* GENERON SUCCESSFULLY CONCLUDES FIRST PHASE III CLINICAL TRIAL OF F-627 FOR CHEMOTHERAPY-INDUCED NEUTROPENIA\n* GENERON CORP- PATIENTS TREATED WITH F-627 DEMONSTRATED SIGNIFICANTLY REDUCED DURATION OF SEVERE NEUTROPENIA COMPARED TO PATENTS IN PLACEBO GROUP â€‹ Source text for Eikon:\n ",
    "published": "2018-01-25T13:14:00.000+02:00",
    "crawled": "2018-01-26T21:07:24.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "generon",
        "successfully",
        "concludes",
        "first",
        "phase",
        "iii",
        "clinical",
        "trial",
        "neutropenia",
        "generon",
        "patient",
        "treated",
        "demonstrated",
        "significantly",
        "reduced",
        "duration",
        "severe",
        "neutropenia",
        "compared",
        "patent",
        "placebo",
        "group",
        "source",
        "text",
        "eikon"
    ]
}